Kimsey Troy F, Cohen T, Patel A, Busam K J, Brady M S
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Ann Surg Oncol. 2009 May;16(5):1176-83. doi: 10.1245/s10434-009-0350-7. Epub 2009 Feb 18.
Microscopic satellitosis in melanoma is uncommon. The role of regional basin staging/therapy in patients with this high-risk feature has not been well defined.
Patients presenting from 1996 to 2005 with clinically localized melanoma containing microscopic satellitosis were identified from a prospective, single-institution database. Multiple factors were analyzed to determine their predictive value for recurrence. The management of the draining nodal basin was evaluated to determine its impact on recurrence and survival.
Thirty-eight patients presented to our institution during this time period with clinically localized melanoma containing microscopic satellitosis. The 5-year overall and disease-free survivals in these patients were 34% and 18%, respectively. Sixty-eight percent had pathologically involved regional nodal metastases. With median follow-up of 21 months, 68% recurred, with a median time to recurrence of 9 months. Lymphovascular invasion (LVI) (p = 0.01), tumor regression (p = 0.04), and positive regional lymph nodes (p = 0.02) were associated with an increased risk of recurrence. Of the 31 patients who underwent sentinel lymph node (SLN) biopsy, 22 had metastasis in the SLN (71%). Fifteen of these patients underwent completion lymphadenectomy (CLND) and seven were observed. There was no difference in disease-free survival (DFS), disease-specific survival (DSS), or overall survival (OS) between these groups (p = 0.42).
Pathological lymph node metastases were more prevalent (68%) than in any group previously defined. Regional nodal status predicted recurrence but not nodal recurrence. In SLN-positive patients, CLND did not improve DFS, DSS, or OS, although the number of patients was small. Further studies are needed to determine the utility of regional nodal staging/therapy in these high-risk patients.
黑色素瘤中的微小卫星灶并不常见。区域淋巴结分期/治疗在具有这种高危特征的患者中的作用尚未明确界定。
从一个前瞻性的单机构数据库中识别出1996年至2005年期间出现的临床局限性黑色素瘤且含有微小卫星灶的患者。分析多个因素以确定它们对复发的预测价值。评估引流淋巴结区域的处理方式以确定其对复发和生存的影响。
在此期间,38例患者因临床局限性黑色素瘤且含有微小卫星灶就诊于本机构。这些患者的5年总生存率和无病生存率分别为34%和18%。68%的患者有病理证实的区域淋巴结转移。中位随访21个月时,68%的患者复发,中位复发时间为9个月。淋巴管浸润(LVI)(p = 0.01)、肿瘤消退(p = 0.04)和区域淋巴结阳性(p = 0.02)与复发风险增加相关。在31例行前哨淋巴结(SLN)活检的患者中,22例SLN有转移(71%)。其中15例患者接受了根治性淋巴结清扫术(CLND),7例进行观察。这些组之间的无病生存率(DFS)、疾病特异性生存率(DSS)或总生存率(OS)无差异(p = 0.42)。
病理淋巴结转移比以往定义的任何组都更普遍(68%)。区域淋巴结状态可预测复发,但不能预测淋巴结复发。在SLN阳性患者中,尽管患者数量较少,但CLND并未改善DFS、DSS或OS。需要进一步研究以确定区域淋巴结分期/治疗在这些高危患者中的效用。